Diagnostic value of joint detection of serum tumor markers in different pathological types of lung cancer.

Background: To evaluate the diagnostic potential of joint testing of serum tumor markers containing cytokeratin fragment antigen 21-1 (CYFRA21-1), progastrinreleasing peptide (ProGRP), carcinoembryonic antigen (CEA) as well as neuron-specific enolase (NSE) in a variety of lung cancer (LC). Materials and Methods: The LC group comprised 150 LC patients who were diagnosed for the first time and were not treated. During the same period, 120 patients harbored benign lung diseases and 120 healthy subjects were respectively designated as the benign group and control group. Immunochemiluminescence assay was implemented to detect tumor markers in serum from three groups and different types of LC. Results: Levels of four serum tumor markers in LC group were elevated relative to control group. CYFRA21-1 level in lung squamous cell carcinoma (LSCC) group was elevated compared to lung adenocarcinoma (LUAD) and small cell lung cancer (SCLC) groups. ProGRP and NSE levels in SCLC group increased compared to LSCC and LUAD groups. CEA level in LUAD group was higher compared to LSCC and SCLC groups. The highest positive rate of LSCC was CYFRA21-1, the highest positive rate of LUAD was CEA and the highest positive rates of SCLC were ProGRP and NSE. In terms of single tumor marker detection, CYFRA21-1 possessed the best diagnostic efficiency for LSCC, CEA possessed the best diagnostic efficiency for LUAD, NSE and ProGRP possessed the best diagnostic efficiency for SCLC, respectively. Conclusion: The individual determination of CYFRA21-1, ProGRP, CEA, and NSE has certain clinical application value for the pathological classification of LC. [ABSTRACT FROM AUTHOR]